O	0	6	CYP2D6
O	7	10	and
O	11	17	UGT2B7
O	18	26	genotype
O	27	30	and
O	31	35	risk
O	36	38	of
O	39	49	recurrence
O	50	52	in
O	53	62	tamoxifen
O	62	63	-
O	63	70	treated
O	71	77	breast
O	78	84	cancer
O	85	93	patients
O	93	94	.

O	95	103	Adjuvant
O	104	113	tamoxifen
O	114	121	therapy
O	122	135	substantially
O	136	145	decreases
O	146	149	the
O	150	154	risk
O	155	157	of
O	158	168	recurrence
O	169	172	and
O	173	182	mortality
O	183	185	in
O	186	191	women
O	192	196	with
O	197	204	hormone
O	205	206	(
O	206	214	estrogen
O	215	218	and
O	218	219	/
O	219	221	or
O	222	234	progesterone
O	234	235	)
O	236	244	receptor
O	244	245	-
O	245	253	positive
O	254	260	breast
O	261	267	cancer
O	267	268	.

O	269	277	Previous
O	278	285	studies
O	286	290	have
O	291	300	suggested
O	301	305	that
O	306	315	metabolic
O	316	326	conversion
O	327	329	of
O	330	339	tamoxifen
O	340	342	to
O	343	352	endoxifen
O	353	355	by
O	356	366	cytochrome
O	367	371	P450
O	372	375	2D6
O	376	377	(
O	377	383	CYP2D6
O	383	384	)
O	385	387	is
O	388	396	required
O	397	400	for
O	401	408	patient
O	409	416	benefit
O	417	421	from
O	422	431	tamoxifen
O	432	439	therapy
O	439	440	.

O	441	446	Tumor
O	447	456	specimens
O	457	461	from
O	462	463	a
O	464	470	subset
O	471	473	of
B-eligibility	474	488	postmenopausal
I-eligibility	489	497	patients
I-eligibility	498	502	with
I-eligibility	503	510	hormone
I-eligibility	511	519	receptor
I-eligibility	519	520	-
I-eligibility	520	528	positive
I-eligibility	529	534	early
I-eligibility	534	535	-
I-eligibility	535	540	stage
I-eligibility	541	542	(
I-eligibility	542	548	stages
I-eligibility	549	550	I
I-eligibility	550	551	,
I-eligibility	552	554	II
I-eligibility	554	555	,
I-eligibility	556	559	and
I-eligibility	560	564	IIIA
I-eligibility	564	565	)
I-eligibility	566	572	breast
I-eligibility	573	579	cancer
O	579	580	,
O	581	584	who
O	585	589	were
O	590	598	enrolled
O	599	601	in
O	602	605	the
O	606	616	randomized
O	617	623	double
O	623	624	-
O	624	629	blind
O	630	638	Arimidex
O	638	639	,
O	640	649	Tamoxifen
O	649	650	,
O	651	656	Alone
O	657	659	or
O	660	662	in
O	663	674	Combination
O	675	676	(
O	676	680	ATAC
O	680	681	)
O	682	690	clinical
O	691	696	trial
O	696	697	,
O	698	702	were
O	703	712	genotyped
O	713	716	for
O	717	725	variants
O	726	728	in
O	729	735	CYP2D6
O	736	737	(
O	737	738	N
O	739	740	=
B-total-participants	741	745	1203
O	746	754	patients
O	754	755	:
B-intervention	756	767	anastrozole
O	768	769	[
O	769	774	trade
O	775	779	name
O	779	780	:
O	781	789	Arimidex
O	789	790	]
O	791	796	group
O	796	797	,
O	798	799	n
O	800	801	=
B-intervention-participants	802	805	615
O	806	814	patients
O	814	815	;
B-control	816	825	tamoxifen
O	826	831	group
O	831	832	,
O	833	834	n
O	835	836	=
B-control-participants	837	840	588
O	841	849	patients
O	849	850	)
O	851	854	and
O	855	858	UDP
O	858	859	-
O	859	882	glucuronosyltransferase
O	882	883	-
O	883	886	2B7
O	887	888	(
O	888	894	UGT2B7
O	894	895	)
O	895	896	,
O	897	902	whose
O	903	907	gene
O	908	915	product
O	916	927	inactivates
O	928	937	endoxifen
O	938	939	(
O	939	940	N
O	941	942	=
B-total-participants	943	947	1209
O	948	956	patients
O	956	957	;
O	958	969	anastrozole
O	970	975	group
O	975	976	,
O	977	978	n
O	979	980	=
B-intervention-participants	981	984	606
O	985	993	patients
O	993	994	;
O	995	1004	tamoxifen
O	1005	1010	group
O	1010	1011	,
O	1012	1013	n
O	1014	1015	=
B-control-participants	1016	1019	603
O	1020	1028	patients
O	1028	1029	)
O	1029	1030	.

O	1031	1041	Genotyping
O	1042	1045	was
O	1046	1055	performed
O	1056	1061	using
O	1062	1072	polymerase
O	1073	1078	chain
O	1079	1087	reaction
O	1087	1088	-
O	1088	1093	based
O	1094	1100	TaqMan
O	1101	1107	assays
O	1107	1108	.

O	1109	1114	Based
O	1115	1117	on
O	1118	1121	the
O	1122	1131	genotypes
O	1132	1135	for
O	1136	1142	CYP2D6
O	1142	1143	,
O	1144	1152	patients
O	1153	1157	were
O	1158	1168	classified
O	1169	1171	as
O	1172	1176	poor
O	1177	1188	metabolizer
O	1189	1190	(
O	1190	1192	PM
O	1192	1193	)
O	1193	1194	,
O	1195	1207	intermediate
O	1208	1219	metabolizer
O	1220	1221	(
O	1221	1223	IM
O	1223	1224	)
O	1224	1225	,
O	1226	1228	or
O	1229	1238	extensive
O	1239	1250	metabolizer
O	1251	1252	(
O	1252	1254	EM
O	1254	1255	)
O	1256	1266	phenotypes
O	1266	1267	.

O	1268	1270	We
O	1271	1280	evaluated
O	1281	1284	the
O	1285	1296	association
O	1297	1299	of
O	1300	1306	CYP2D6
O	1307	1310	and
O	1311	1317	UGT2B7
O	1318	1326	genotype
O	1327	1331	with
B-outcome-Measure	1332	1339	distant
I-outcome-Measure	1340	1350	recurrence
O	1351	1352	(
O	1352	1359	primary
O	1360	1368	endpoint
O	1368	1369	)
O	1370	1373	and
B-outcome-Measure	1374	1377	any
I-outcome-Measure	1378	1388	recurrence
O	1389	1390	(
O	1390	1399	secondary
O	1400	1408	endpoint
O	1408	1409	)
O	1410	1412	by
O	1413	1423	estimating
O	1424	1427	the
O	1428	1434	hazard
O	1435	1441	ratios
O	1442	1443	(
O	1443	1446	HRs
O	1446	1447	)
O	1448	1451	and
O	1452	1465	corresponding
O	1466	1468	95
O	1468	1469	%
O	1470	1480	confidence
O	1481	1490	intervals
O	1491	1492	(
O	1492	1495	CIs
O	1495	1496	)
O	1497	1502	using
O	1503	1506	Cox
O	1507	1519	proportional
O	1520	1527	hazards
O	1528	1534	models
O	1534	1535	.

O	1536	1539	All
O	1540	1551	statistical
O	1552	1557	tests
O	1558	1562	were
O	1563	1566	two
O	1566	1567	-
O	1567	1572	sided
O	1572	1573	.

O	1574	1579	After
O	1580	1581	a
O	1582	1588	median
O	1589	1595	follow
O	1595	1596	-
O	1596	1598	up
O	1599	1601	of
O	1602	1604	10
O	1605	1610	years
O	1610	1611	,
O	1612	1614	no
O	1615	1628	statistically
O	1629	1640	significant
O	1641	1653	associations
O	1654	1658	were
O	1659	1667	observed
O	1668	1675	between
O	1676	1682	CYP2D6
O	1683	1691	genotype
O	1692	1695	and
B-outcome	1696	1706	recurrence
O	1707	1709	in
O	1710	1719	tamoxifen
O	1719	1720	-
O	1720	1727	treated
O	1728	1736	patients
O	1737	1738	(
O	1738	1740	PM
O	1741	1743	vs
O	1744	1746	EM
O	1746	1747	:
O	1748	1750	HR
O	1751	1754	for
O	1755	1762	distant
O	1763	1773	recurrence
O	1774	1775	=
O	1776	1777	1
O	1777	1778	.
O	1778	1780	25
O	1780	1781	,
O	1782	1784	95
O	1784	1785	%
O	1786	1788	CI
O	1789	1790	=
O	1791	1792	0
O	1792	1793	.
O	1793	1795	55
O	1796	1798	to
O	1799	1800	3
O	1800	1801	.
O	1801	1803	15
O	1803	1804	,
O	1805	1806	P
O	1807	1808	=
O	1809	1810	.
O	1810	1812	64
O	1812	1813	;
O	1814	1816	HR
O	1817	1820	for
O	1821	1824	any
O	1825	1835	recurrence
O	1836	1837	=
O	1838	1839	0
O	1839	1840	.
O	1840	1842	99
O	1842	1843	,
O	1844	1846	95
O	1846	1847	%
O	1848	1850	CI
O	1851	1852	=
O	1853	1854	0
O	1854	1855	.
O	1855	1857	48
O	1858	1860	to
O	1861	1862	2
O	1862	1863	.
O	1863	1865	08
O	1865	1866	,
O	1867	1868	P
O	1869	1870	=
O	1871	1872	.
O	1872	1874	99
O	1874	1875	)
O	1875	1876	.

O	1877	1878	A
O	1879	1883	near
O	1883	1884	-
O	1884	1888	null
O	1889	1900	association
O	1901	1904	was
O	1905	1913	observed
O	1914	1921	between
O	1922	1928	UGT2B7
O	1929	1937	genotype
O	1938	1941	and
B-outcome	1942	1952	recurrence
O	1953	1955	in
O	1956	1965	tamoxifen
O	1965	1966	-
O	1966	1973	treated
O	1974	1982	patients
O	1982	1983	.

O	1984	1986	No
O	1987	1999	associations
O	2000	2004	were
O	2005	2013	observed
O	2014	2021	between
O	2022	2028	CYP2D6
O	2029	2032	and
O	2033	2039	UGT2B7
O	2040	2049	genotypes
O	2050	2053	and
B-outcome	2054	2064	recurrence
O	2065	2067	in
O	2068	2079	anastrozole
O	2079	2080	-
O	2080	2087	treated
O	2088	2096	patients
O	2096	2097	.

O	2098	2101	The
O	2102	2109	results
O	2110	2112	do
O	2113	2116	not
O	2117	2124	support
O	2125	2128	the
O	2129	2139	hypothesis
O	2140	2144	that
O	2145	2151	CYP2D6
O	2152	2160	genotype
O	2161	2169	predicts
O	2170	2178	clinical
O	2179	2186	benefit
O	2187	2189	of
O	2190	2198	adjuvant
O	2199	2208	tamoxifen
O	2209	2218	treatment
O	2219	2224	among
O	2225	2239	postmenopausal
O	2240	2246	breast
O	2247	2253	cancer
O	2254	2262	patients
O	2262	2263	.
